Compare BSEM & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSEM | FBIO |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.9M | 90.7M |
| IPO Year | 2026 | 2011 |
| Metric | BSEM | FBIO |
|---|---|---|
| Price | $4.68 | $2.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 102.5K | ★ 302.2K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.40 |
| EPS | N/A | ★ 2.86 |
| Revenue | N/A | ★ $63,262,000.00 |
| Revenue This Year | N/A | $55.22 |
| Revenue Next Year | N/A | $40.55 |
| P/E Ratio | ★ N/A | $0.88 |
| Revenue Growth | N/A | ★ 9.69 |
| 52 Week Low | $2.25 | $2.18 |
| 52 Week High | $4.66 | $4.53 |
| Indicator | BSEM | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 67.59 | 38.36 |
| Support Level | $3.90 | $2.19 |
| Resistance Level | N/A | $3.02 |
| Average True Range (ATR) | 0.42 | 0.09 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 83.53 | 33.53 |
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.